Patients with Type 2 diabetes who were treated with the newer generation of insulin analog drugs did not have substantially better outcomes than those treated with less costly human insulin, according to a study by Yale School of Medicine Researchers and Colleagues with one healthcare company. The study is published in the Journal of the American Medical Association. The lead author of study said we compared the newer and older types of insulin in a large and diverse population of type 2 diabetes patients who were newly prescribed insulin.
We found that for patients with type 2 diabetes in usual practice, the use of the more expensive insulin analogs did not appear to result in better safety at least as defined by hospital or emergency visits for hypoglycemia or better blood sugar control compared with NPH insulin. This suggests that many people with type 2 diabetes should consider…
